Literature DB >> 16988055

Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia.

Christopher Katnik1, Waldo R Guerrero, Keith R Pennypacker, Yelenis Herrera, Javier Cuevas.   

Abstract

Sigma receptors are putative targets for neuroprotection following ischemia; however, little is known on their mechanism of action. One of the key components in the demise of neurons following ischemic injury is the disruption of intracellular calcium homeostasis. Fluorometric calcium imaging was used to examine the effects of sigma receptor activation on changes in intracellular calcium concentrations ([Ca(2+)](i)) evoked by in vitro ischemia in cultured cortical neurons from embryonic rats. The sigma receptor agonist, 1,3-di-o-tolyl-guanidine (DTG), was shown to depress [Ca(2+)](i) elevations observed in response to ischemia induced by sodium azide and glucose deprivation. Two sigma receptor antagonists, metaphit [1-(1-(3-isothiocyanatophenyl)-cyclohexyl)-piperidine] and BD-1047 (N-[2-3,4-dichlorophenyl)-ethyl]-N-methyl-2-(dimethylamino)ethylamine), were shown to blunt the ability of DTG to inhibit ischemia-evoked increases in [Ca(2+)](i), revealing that the effects are mediated by activation of sigma receptors and not via the actions of DTG on nonspecific targets such as N-methyl-d-aspartate receptors. DTG inhibition of ischemia-induced increases in [Ca(2+)](i) was mimicked by the sigma-1 receptor-selective agonists, carbetapentane, (+)-pentazocine and PRE-084 [2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochloride], but not by the sigma-2-selective agonist, ibogaine, showing that activation of sigma-1 receptors is responsible for the effects. In contrast, DTG, carbetapentane, and ibogaine blocked spontaneous, synchronous calcium transients observed in our preparation at concentrations consistent with sigma receptor-mediated effects, indicating that both sigma-1 and sigma-2 receptors regulate events that affect [Ca(2+)](i) in cortical neurons. Our studies show that activation of sigma receptors can ameliorate [Ca(2+)](i) dysregulation associated with ischemia in cortical neurons and, thus, identify one of the mechanisms by which these receptors may exert their neuroprotective properties.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988055     DOI: 10.1124/jpet.106.107557

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  The sigma-1 receptor chaperone as an inter-organelle signaling modulator.

Authors:  Tsung-Ping Su; Teruo Hayashi; Tangui Maurice; Shilpa Buch; Arnold E Ruoho
Journal:  Trends Pharmacol Sci       Date:  2010-10-01       Impact factor: 14.819

Review 2.  PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation.

Authors:  Zeinab Y Motawe; Salma S Abdelmaboud; Javier Cuevas; Jerome W Breslin
Journal:  Int J Biochem Cell Biol       Date:  2020-07-12       Impact factor: 5.085

3.  Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons.

Authors:  Zeng-Jin Yang; Erin L Carter; Michel T Torbey; Lee J Martin; Raymond C Koehler
Journal:  Exp Neurol       Date:  2009-10-31       Impact factor: 5.330

Review 4.  Sigma receptors as potential therapeutic targets for neuroprotection.

Authors:  Linda Nguyen; Nidhi Kaushal; Matthew J Robson; Rae R Matsumoto
Journal:  Eur J Pharmacol       Date:  2014-09-27       Impact factor: 4.432

5.  σ-1 Receptor Inhibition of ASIC1a Channels is Dependent on a Pertussis Toxin-Sensitive G-Protein and an AKAP150/Calcineurin Complex.

Authors:  Yelenis Mari; Christopher Katnik; Javier Cuevas
Journal:  Neurochem Res       Date:  2014-06-13       Impact factor: 3.996

6.  Implications of immune system in stroke for novel therapeutic approaches.

Authors:  Aaron A Hall; Keith R Pennypacker
Journal:  Transl Stroke Res       Date:  2010-01-13       Impact factor: 6.829

7.  In vitro evaluation of guanidine analogs as sigma receptor ligands for potential anti-stroke therapeutics.

Authors:  Adam A Behensky; Michelle Cortes-Salva; Michael J Seminerio; Rae R Matsumoto; Jon C Antilla; Javier Cuevas
Journal:  J Pharmacol Exp Ther       Date:  2012-10-12       Impact factor: 4.030

Review 8.  A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.

Authors:  Ede Frecska; Attila Szabo; Michael J Winkelman; Luis E Luna; Dennis J McKenna
Journal:  J Neural Transm (Vienna)       Date:  2013-04-26       Impact factor: 3.575

Review 9.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.